Biotech · Private company
Aeglea Biotherapeutics
Track this companyFree. Adds Aeglea Biotherapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials70 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- AEB1102Phase 2 · Arginase I DeficiencyClinicalTrials.gov · fetched Nov 12, 2026
- Pegtarviliase IVPhase 2 · Homocystinuria Due to Cystathionine Beta-Synthase DeficiencyClinicalTrials.gov · fetched Nov 12, 2026
- Pegtarviliase SCPhase 2 · Homocystinuria Due to Cystathionine Beta-Synthase DeficiencyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- A Multiple Ascending Dose Study of ACN00177 (Pegtarviliase) in Subjects With CBS DeficiencyPHASE1_PHASE2 · TERMINATED · started May 13, 2021ClinicalTrials.gov NCT05154890 · fetched Nov 12, 2026
- Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 DeficiencyPHASE3 · COMPLETED · started May 1, 2019ClinicalTrials.gov NCT03921541 · fetched Nov 12, 2026
- Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung CancerPHASE1_PHASE2 · TERMINATED · started Dec 21, 2017ClinicalTrials.gov NCT03371979 · fetched Nov 12, 2026
- A Study of AEB1102 (Pegzilarginase) in Patients With Arginase 1 DeficiencyPHASE2 · COMPLETED · started Dec 7, 2017ClinicalTrials.gov NCT03378531 · fetched Nov 12, 2026
- A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDSPHASE1 · COMPLETED · started Aug 15, 2016ClinicalTrials.gov NCT02732184 · fetched Nov 12, 2026
- A Phase 1/2 Study of AEB1102 in Patients With Arginase I DeficiencyPHASE1_PHASE2 · COMPLETED · started Jun 1, 2016ClinicalTrials.gov NCT02488044 · fetched Nov 12, 2026
- A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid TumorsPHASE1 · COMPLETED · started Oct 22, 2015ClinicalTrials.gov NCT02561234 · fetched Nov 12, 2026